Why does EGFR-targeted therapy continue to fail in breast cancer? From mechanistic deciphering to novel intervention strategies

Puntos clave

• EGFR-targeted therapy continues to fail in breast cancer treatment, impacting patient outcomes.
• The study explores mechanistic pathways that contribute to resistance in approximately 30% of cases.
• Observational analysis identifies specific biomarkers that may inform future targeted therapies.
• These findings highlight the complexity of tumor resistance, suggesting that further intervention strategies are urgently needed.